Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25920685 | 0.82 | LMNA (0.66) | ALDH1A1L3MBTL1LMNAUSP2TSHR | |
| SCHEMBL25920681 | 0.79 | LMNA (0.69) | ALDH1A1L3MBTL1LMNAUSP2TSHR | |
| SCHEMBL10022667 | 0.79 | LMNA (0.68) | ALDH1A1L3MBTL1LMNAUSP2TSHR | |
| SCHEMBL24125225 | 0.77 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1USP2TSHRNPSR1 | |
| SCHEMBL30270516 | 0.74 | LMNA (1.00) | ALDH1A1L3MBTL1LMNAUSP2TSHR | |
| SCHEMBL2636675 | 0.74 | LMNA (1.00) | ALDH1A1L3MBTL1LMNAUSP2TSHR | |
| SCHEMBL24124853 | 0.72 | LMNA (0.70) | ALDH1A1L3MBTL1LMNAUSP2TSHR | |
| SCHEMBL23768992 | 0.71 | ALDH1A1 (0.71) | ALDH1A1LMNANPSR1SMN1; SMN2POLB | |
| SCHEMBL31411772 | 0.71 | LMNA (0.60) | ALDH1A1L3MBTL1LMNAUSP2TSHR | |
| SCHEMBL29978848 | 0.71 | ALDH1A1 (0.71) | ALDH1A1LMNANPSR1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2021257544-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | ALDH1A1 2654/4885L3MBTL1 1424/4885LMNA 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.